ArticleJournal of the National Cancer Institute2026
Opioid limiting law and opioid prescriptions among Medicaid-enrolled survivors of childhood cancer.
Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundMany U.S. states have enacted opioid-limiting laws to curb the opioid epidemic, often capping opioid prescriptions at seven days. How these laws affect opioid prescribing among long-term survivors of childhood cancer remains unclear.
methodsUsing Medicaid claims linked to the Childhood Cancer Survivor Study, we identified childhood cancer survivors aged 18-64 years continuously enrolled in Medicaid ≥1 year during 2009-2019. Primary outcomes were any opioid prescription fill and opioid prescription with >7 days' supply. Secondary outcomes included total number of opioid prescriptions, total days of supply, and mean morphine milligram equivalents per supply day. Difference-in-differences models assessed associations between opioid-limiting law implementation and outcomes, adjusting for sociodemographic and clinical characteristics.
resultsWe identified 2,351 survivors (57.0% female, 43.9% aged 18-29 years, 10.2% non-Hispanic Black, 9.7% Hispanic), with 15,323 person-years. Overall, 20.5% filled any opioid prescription, and 9.4% filled prescriptions with >7 days' supply. Opioid-limiting laws were associated with 1.77 percentage points (ppt; p=0.047) reduced likelihood of filling any opioid prescription with >7 days' supply. Associations with other outcomes were not statistically significant. In subgroup analyses, survivors with second cancer experienced statistically significant declines in any opioid prescriptions (-6.96 ppt, p=0.034), prescriptions with >7 days' supply (-7.79 ppts, p=0.001), total number of prescriptions (-0.42, p=0.019), and total days of supply (-7.40 days, p=0.003) following law implementation.
conclusionsWhile opioid-limiting laws were not associated with meaningful reductions in opioid prescribing among Medicaid-enrolled adult survivors of childhood cancer overall, notable declines were observed among subgroups with potentially higher pain care needs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.